Press Room http://www.news.sanofi.us/ MediaRoom Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis http://www.news.sanofi.us/Sanofi-and-Regeneron-Announce-Positive-Phase-2-Study-Results-for-Dupilumab-in-Patients-With-Active-Moderate-to-Severe-Eosinophilic-Esophagitis - Late-breaking oral abstract presented at the World Congress of Gastroenterology - Mon, 16 Oct 2017 08:07:00 -0400 http://www.news.sanofi.us/Sanofi-and-Regeneron-Announce-Positive-Phase-2-Study-Results-for-Dupilumab-in-Patients-With-Active-Moderate-to-Severe-Eosinophilic-Esophagitis Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis http://www.news.sanofi.us/2017-10-11-Internationally-Acclaimed-Writer-and-Executive-Producer-of-HBOs-The-Night-Of-Reveals-His-Personal-Story-Detailing-the-Harsh-Realities-of-Atopic-Dermatitis - Understand AD: A Day in the Life, Raises Awareness of Atopic Dermatitis by Sharing Real Stories from the AD Community, Driving Empathy and Understanding of this Unrelenting, Chronic Disease - Wed, 11 Oct 2017 08:00:00 -0400 http://www.news.sanofi.us/2017-10-11-Internationally-Acclaimed-Writer-and-Executive-Producer-of-HBOs-The-Night-Of-Reveals-His-Personal-Story-Detailing-the-Harsh-Realities-of-Atopic-Dermatitis Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab) http://www.news.sanofi.us/2017-10-05-Appellate-Court-Orders-a-New-Trial-and-Vacates-Permanent-Injunction-in-Ongoing-Patent-Case-Regarding-Praluent-R-alirocumab - Praluent continues to be available to patients in the U.S. - Thu, 05 Oct 2017 12:30:00 -0400 http://www.news.sanofi.us/2017-10-05-Appellate-Court-Orders-a-New-Trial-and-Vacates-Permanent-Injunction-in-Ongoing-Patent-Case-Regarding-Praluent-R-alirocumab Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union http://www.news.sanofi.us/Sanofi-and-Regeneron-Announce-Approval-of-Dupixent-R-dupilumab-to-Treat-Adult-Patients-with-Moderate-to-Severe-Atopic-Dermatitis-in-the-European-Union - First targeted biologic in the European Union to receive marketing authorization for use in atopic dermatitis - Thu, 28 Sep 2017 07:22:00 -0400 http://www.news.sanofi.us/Sanofi-and-Regeneron-Announce-Approval-of-Dupixent-R-dupilumab-to-Treat-Adult-Patients-with-Moderate-to-Severe-Atopic-Dermatitis-in-the-European-Union Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS http://www.news.sanofi.us/2017-09-20-Sanofi-and-NIH-researchers-develop-three-in-one-antibodies-as-a-potential-breakthrough-intervention-for-HIV-AIDS - In preclinical studies, trispecific antibodies show exceptional potency against diverse HIV viruses - Wed, 20 Sep 2017 14:01:00 -0400 http://www.news.sanofi.us/2017-09-20-Sanofi-and-NIH-researchers-develop-three-in-one-antibodies-as-a-potential-breakthrough-intervention-for-HIV-AIDS